Unlock instant, AI-driven research and patent intelligence for your innovation.

Tumor lysate loaded particles

a technology of tumor lysate and loaded particles, which is applied in the direction of snake antigen ingredients, drug compositions, antibody medical ingredients, etc., can solve the problems of limited ability, limited mapability, and ineffective simple presentation of tumor antigens to the immune system in the foregoing manner

Inactive Publication Date: 2014-03-06
ORBIS HEALTH SOLUTIONS
View PDF6 Cites 10 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The patent text describes an isolated dendritic cell that contains a phagocytosed component consisting of a particle and a tumor lysate. The tumor lysate can be from a variety of cancer types such as breast cancer, lung cancer, glioma, and melanoma. The dendritic cell can be produced by a method that involves loading the tumor lysate into a particle, freeze-drying it, and then incubating it with a dendritic cell. The isolated dendritic cell can then be used as a vaccine to treat cancer. The technical effect is a more effective immunotherapy for cancer that targets tumor-specific antigens and enhances immune responses.

Problems solved by technology

However, simply presenting tumor antigens to the immune system in the foregoing manner has not been effective because such antigens were merely endocytosed by the dendritic cells and generally presented through the Major Histocompatibility Complex (MHC) class II, which elicits only helper T cells and does not provide a robust immune response.
However, these methods have disadvantages, including (1) a limited ability to identify all of the important tumor-specific antigens, (2) a limited ability to map the genes of specific tumor antigens, (3) only one or a small number of known tumor antigen genes can be introduced into a dendritic cell and (4) the methods are time-consuming and cumbersome.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Tumor lysate loaded particles
  • Tumor lysate loaded particles
  • Tumor lysate loaded particles

Examples

Experimental program
Comparison scheme
Effect test

example 1

Preparing Dendritic Cells

[0061]Dendritic cells were generated from a patient's PBMCs. PBMCs were collected from the patient by a blood draw of 200 ml following standard operating procedures. The blood was then transferred to 250 ml centrifuge tubes and diluted 1:1 with 1×PBS. Then, 35 ml of the diluted blood was layered over 15 ml of room temperature Lymphocyte Separation Medium (LSM; Mediatech) in 50 ml tubes and centrifuged at 1000 g for 20 minutes at room temperature. The PBMC layers were removed by pipetting from the LSM gradients and placed into clean 50 ml centrifuge tubes. Four volumes of 1×PBS were added and the tubes were inverted to mix the contents. The PBMCs were then centrifuged at 500 g at room temperature for 5 minutes. Ten ml of 1×PBS were added into each tube and the cells were resuspended and pooled into 1 tube. The PBMCs were again centrifuged at 500 g at room temperature for 10 minutes, resuspended in 20 to 40 ml of ACK lysing solution (Cambrex) and incubated at ...

example 2

Preparing Tumor Lysate

[0063]A tumor sample was obtained from a patient. After separating fat and necrotic tissue away from the tumor tissue, the tissue was weighed and 1×PBS added (50 μL of PBS per 200 μg of tissue) and the tumor was minced thoroughly with scalpels in 1×PBS. The tumor cells were then subjected to 4 cycles of freeze and thaw. The freezing was performed in liquid nitrogen for 20 minutes and the thawing was performed at room temperature. Prepared tumor lysate was quantified by a spectrophotometer. An aliquot was taken for quality control testing. The remainder was stored at ≦−135° C. in preparation for vaccine preparation.

[0064]FIG. 2 provides an overview of the tumor cell lysate processing.

example 3

Preparing YCWP

[0065]YCWPs were prepared from Fleishmans Baker's Yeast. Briefly, 10 g of Fleishmans Baker's yeast was suspended in 100 ml of 1 M NaOH and heated to 80° C. for one hour. The undissolved yeast cell walls were recovered by centrifugation at 2000×g for 10 minutes. The recovered yeast cell walls were then resuspended in 100 ml of water with the pH adjusted to 4.5 with HCl and incubated at 55° C. for an additional hour, and subsequently recovered by centrifugation. The recovered YCWPs were then washed with water once, isopropanol 4 times and finally acetone 2 times. Once the YCWPs were fully dried they were resuspended in PBS, counted, aliquoted into groups of 1×109 particles and freeze dried for use in manufacturing the vaccine.

[0066]FIG. 3 provides an overview of the yeast cell wall particles processing.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Temperatureaaaaaaaaaa
Timeaaaaaaaaaa
Massaaaaaaaaaa
Login to View More

Abstract

Dendritic cells containing tumor lysate loaded particles are prepared. The dendritic cells present tumor antigens to elicit the Major Histocompatibility Complex class I pathway and can be used as a vaccine to treat cancer, including ocular melanoma.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS[0001]This application claims priority from U.S. provisional application No. 61 / 697,498, filed Sep. 6, 2012.BACKGROUND OF THE INVENTION[0002]A tumor cell exists in part because it has selected for one or more mutations that allows it to partially or completely escape immune surveillance in vivo.[0003]In an attempt to elicit an immune response to a tumor cell, previous researchers have used dendritic cells, which are professional antigen-presenting cells, to present tumor antigens to the immune system. For example, dendritic cells pulsed with peptide or tumor lysate have been used to vaccinate melanoma patients.[0004]However, simply presenting tumor antigens to the immune system in the foregoing manner has not been effective because such antigens were merely endocytosed by the dendritic cells and generally presented through the Major Histocompatibility Complex (MHC) class II, which elicits only helper T cells and does not provide a robust immune...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C12N5/0784A61K35/15A61K39/00
CPCC12N5/0639A61K2039/572A61P35/00A61K2239/38A61K39/4615A61K2239/55A61K2239/31A61K39/464499A61K39/4622A61K35/15A61K39/0011A61K2039/5154
Inventor WAGNER, THOMAS E.
Owner ORBIS HEALTH SOLUTIONS